Innovative Medicine
-
Subcutaneous VELCADE® Approved In the EU for the Treatment of Multiple Myeloma
Simpler, easier route of administration offers improved safety and convenience, with maintained efficacy -
FDA Approves Expansion of Dosing Window to Help Avoid Missed Doses in INVEGA® SUSTENNA® Updated Product Label
Additional Prescribing Information Revisions Also Reflected in Updated Product Label -
-
Johnson & Johnson Symposium Honors 2012 Recipients of the Dr. Paul Janssen Award for Biomedical Research
Dr. Victor Ambros and Dr. Gary Ruvkun Honored for Discovery of microRNAs;Symposium Celebrates the Power of Science to Change the World -
Janssen Research & Development Submits Complete Response to the U.S. FDA on XARELTO® (rivaroxaban) for the Reduction of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
Supplemental New Drug Application for XARELTO® to reduce the risk of stent thrombosis in patients with acute coronary syndrome also resubmitted -
-
Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
Compound in Development for Multiple Myeloma -
-
FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy
Clinical Trial Data Demonstrate Efficacy and Safety for First Opioid Indicated for Patients with Painful Diabetic Peripheral Neuropathy